Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Jun 1;50(6):e526-e538.
doi: 10.1097/CCM.0000000000005441. Epub 2022 Jan 12.

Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation: Differences Between COVID-19 and Other Viral Acute Respiratory Distress Syndrome

Benjamin Seeliger  1 , Michael Doebler  2 , Daniel Andrea Hofmaenner  3 , Pedro D Wendel-Garcia  3 , Reto A Schuepbach  3 , Julius J Schmidt  4 , Tobias Welte  1 , Marius M Hoeper  1 , Hans-Jörg Gillmann  5 , Christian Kuehn  6 , Stefan Felix Ehrentraut  2 , Jens-Christian Schewe  2 , Christian Putensen  2 , Klaus Stahl  7 , Christian Bode  2 , Sascha David  3
Affiliations
Multicenter Study

Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation: Differences Between COVID-19 and Other Viral Acute Respiratory Distress Syndrome

Benjamin Seeliger et al. Crit Care Med. .

Abstract

Objectives: Extracorporeal membrane oxygenation (ECMO) is a potentially lifesaving procedure in acute respiratory distress syndrome (ARDS) due to COVID-19. Previous studies have shown a high prevalence of clinically silent cerebral microbleeds in patients with COVID-19. Based on this fact, together with the hemotrauma and the requirement of therapeutic anticoagulation on ECMO support, we hypothesized an increased risk of intracranial hemorrhages (ICHs). We analyzed ICH occurrence rate, circumstances and clinical outcome in patients that received ECMO support due to COVID-19-induced ARDS in comparison to viral non-COVID-19-induced ARDS intracerebral hemorrhage.

Design: Multicenter, retrospective analysis between January 2010 and May 2021.

Setting: Three tertiary care ECMO centers in Germany and Switzerland.

Patients: Two-hundred ten ARDS patients on ECMO support (COVID-19, n = 142 vs viral non-COVID, n = 68).

Interventions: None.

Measurements and main results: Evaluation of ICH occurrence rate, parameters of coagulation and anticoagulation strategies, inflammation, and ICU survival. COVID-19 and non-COVID-19 ARDS patients showed comparable disease severity regarding Sequential Organ Failure Assessment score, while the oxygenation index before ECMO cannulation was higher in the COVID group (82 vs 65 mm Hg). Overall, ICH of any severity occurred in 29 of 142 COVID-19 patients (20%) versus four of 68 patients in the control ECMO group (6%). Fifteen of those 29 ICH events in the COVID-19 group were classified as major (52%) including nine fatal cases (9/29, 31%). In the control group, there was only one major ICH event (1/4, 25%). The adjusted subhazard ratio for the occurrence of an ICH in the COVID-19 group was 5.82 (97.5% CI, 1.9-17.8; p = 0.002). The overall ICU mortality in the presence of ICH of any severity was 88%.

Conclusions: This retrospective multicenter analysis showed a six-fold increased adjusted risk for ICH and a 3.5-fold increased incidence of ICH in COVID-19 patients on ECMO. Prospective studies are needed to confirm this observation and to determine whether the bleeding risk can be reduced by adjusting anticoagulation strategies.

Trial registration: ClinicalTrials.gov NCT04853953.

PubMed Disclaimer

Conflict of interest statement

Dr. Seeliger is supported by Program of Hannover Medical School for Clinician Scientists (PRACTIS), funded by the Deutsche Forschungsgemeinschaft (DFG, ME 3696/3-1) and the German Center for Lung Research (DZL). Dr. David received funding from the German Centre for Lung Research. Dr. Hoeper received funding from Acceleron, Actelion, Bayer, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, and Pfizer. Dr. Putensen’s institution received funding from the DFG (PU 219/2-3); he received funding from Pluristem Ltd and Dräger Medical. Dr. Bode is supported by the DFG (BO 3640/2-1) and the Federal Ministry of Education and Research (01KI20343). Dr. David’s institution received funding from the German Research Foundation (DA1209/4-3), DFG, DZL, Cytobsorbents, Octapharma, and Terumo; he received funding from Terumo, Octapharma, and Cytosorbents. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Primary endpoint of intracranial hemorrhage (ICH) in COVID-19 and other viral acute respiratory distress syndromes. Cumulative incidence function for ICH and death from other causes (competing event) in venovenous extracorporeal membrane oxygenation patients with COVID-19 versus controls (CTRL) (A). Cumulative incidence of ICH and death as multistate comparison is shown in (B) demonstrating increased incidence of ICH in COVID-19 patients. Multivariable competing risk regression model using study site as a random-effect term with subhazard ratios (SHRs) and 97.5% CIs (C). BMI = body mass index, IQR = interquartile range, SOFA = Sequential Organ Failure Assessment, UFH = unfractionated heparin.
Figure 2.
Figure 2.
Impact of intracranial hemorrhage (ICH) on mortality and anticoagulation regimens. Kaplan-Meier survival curve stratified by presence of intracranial hemorrhage ICH for the entire cohort (COVID-19 and controls) demonstrating ICH as a risk factor for mortality (A) and multivariable Cox regression model for 90-d ICU mortality using study site as a random-effect term (B). Comparison of mean unfractionated heparin (UFH) dose per kg bodyweight over the first 7 d of extracorporeal membrane oxygenation (ECMO) between COVID-19 and controls (C). Comparison of UFH dose per kg bodyweight over the first 7 d of ECMO stratified by anticoagulation strategy in the COVID-19 cohort (D). ACT = activated clotting time, aPTT = activated partial thromboplastin time, BMI = body mass index, HR = hazard ratio, IU = international units, SOFA = Sequential Organ Failure Assessment.
See this image and copyright information in PMC

Comment in

References

    1. Wu C, Chen X, Cai Y, et al. : Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180:934–943 - PMC - PubMed
    1. Wendel Garcia PD, Fumeaux T, Guerci P, et al. ; RISC-19-ICU Investigators: Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine 2020; 25:100449. - PMC - PubMed
    1. Shekar K, Badulak J, Peek G, et al. ; ELSO Guideline Working Group: Extracorporeal life support organization coronavirus disease 2019 interim guidelines: A consensus document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers. ASAIO J 2020; 66:707–721 - PMC - PubMed
    1. Doyle AJ, Hunt BJ, Sanderson B, et al. : A comparison of thrombosis and hemorrhage rates in patients with severe respiratory failure due to coronavirus disease 2019 and influenza requiring extracorporeal membrane oxygenation. Crit Care Med 2021; 49:e663–e672 - PubMed
    1. Barbaro RP, MacLaren G, Boonstra PS, et al. ; Extracorporeal Life Support Organization: Extracorporeal membrane oxygenation support in COVID-19: An international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020; 396:1071–1078 - PMC - PubMed

Publication types

MeSH terms

Associated data